Staphylococcus aureus mutants selected by BMS-284756.
BMS-284756, a novel des-fluoro(6)-quinolone, was used to select for in vitro mutants of Staphylococcus aureus ISP794. Step mutants were obtained, and the quinolone resistance-determining regions of four target genes, gyrA, gyrB, grlA, and grlB, were sequenced. The data suggest that DNA gyrase is the primary target for BMS-284756 in S. aureus.
Discotto
L F
LF
Bristol-Myers Squibb Pharmaceutical Research Institute, Infectious Diseases, Department of Microbiology, Wallingford, Connecticut 06492, USA. Linda.Discotto@bms.com
Lawrence
L E
LE
Denbleyker
K L
KL
Barrett
J F
JF
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D027081:DNA Gyrase / Q000187:drug effects / Q000235:genetics; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D004352:Drug Resistance, Microbial; D024841:Fluoroquinolones; D007211:Indoles; D009154:Mutation / Q000235:genetics; D015363:Quinolones; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000378:metabolism*
D000890:Anti-Infective Agents; D004269:DNA, Bacterial; D024841:Fluoroquinolones; D007211:Indoles; D015363:Quinolones; D002939:Ciprofloxacin; D027081:DNA Gyrase; C419689:garenoxacin